Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis
Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis
NCT ID: NCT07249229 Phase: PHASE2 Status: COMPLETED Enrollment: 50 Completion: 2021-03-08
Conditions
End-stage Renal Disease (ESRD), Hemodialysis
Interventions
L-carnitine 1000 Mg, Placebo
Summary
The goal of this clinical trial is to evaluate whether oral L-carnitine supplementation helps reduce inflammation and improve nutritional status in patients with end-stage kidney disease who are undergoing long-term hemodialysis.
A total of 50 participants will be randomly assigned to receive either:
- Oral L-carnitine solution (1 g, three times per week after dialysis), or
- A placebo solution that looks and tastes the same but does not contain L-carnitine.
The study will last for three months. Researchers will assess changes in:
- Inflammatory markers (high-sensitivity C-reactive protein, hs-CRP)
- Nutritional markers (serum albumin, ferritin)
- Blood lipid profile (cholesterol, LDL, HDL, triglycerides)
The findings from this study are expected to provide insights into the potential clinical benefits of oral L-carnitine supplementation in maintenance hemodialysis patients.
Primary Outcome
hs-CRP levels (high sensitivity C-reactive protein)